A recent study published in Critical Care Medicine explores the comparative effectiveness of baricitinib and tocilizumab in hospitalized COVID-19 patients. Utilizing data from the National COVID Cohort Collaborative (N3C)—the largest electronic health records database on COVID-19 in the U.S.—this multicenter, retrospective cohort study analyzed outcomes from over 10,000 patients across 75 hospitals.

  • The study revealed that baricitinib was associated with:
  • Lower 28-day mortality (OR: 0.91; 95% CI: 0.85–0.98) compared to tocilizumab.
  • Reduced hospital mortality (OR: 0.88; 95% CI: 0.82–0.94).
  • Shorter hospital stays (IRR: 0.92; 95% CI: 0.90–0.94).
  • Lower rates of hospital-acquired infections (OR: 0.86; 95% CI: 0.75–0.99).
  • Interestingly, there was no significant difference in ICU length of stay between the two groups.
  • These findings suggest that baricitinib may offer clinical advantages over tocilizumab in reducing mortality and improving hospital outcomes for COVID-19 patients.
Post Views: 1,007